Staar Surgical Expects Fourth Quarter ICL Sales to Rise 42%; China Units Nearly Double, U.S. Market Returns to Growth

Source: Staar Surgical Company

Staar Surgical, which provided preliminary sales results for the fourth quarter ending December 28, 2018, said it expects fourth quarter ICL net sales to increase approximately 42% over the prior year period. Total net sales for the fourth quarter are expected to be approximately $31.2 million and total net sales for fiscal 2018 are expected to be approximately $124 million, representing approximately 37% growth over fiscal 2017.

“Global demand for our ICL product lines continued to expand during the fourth quarter, and all signs currently point to this momentum continuing into 2019,” Caren Mason, President and CEO, said in a company news release. “China led the way with ICL unit growth of approximately 99% in the fourth quarter, sequentially consistent with the growth we reported for the third quarter of 2018. As we planned, Staar Surgical’s business in the U.S. also returned to growth. We began the staged rollout of the Toric ICL in the U.S. to certified surgeons in late October leading to approximately 16% growth for the ICL in the U.S., compared to the prior year period, in the world’s second largest refractive surgery market.”

Staar Surgical intends to report full fourth quarter and fiscal 2018 financial results on or about February 21, 2019 and provided today’s information due to investor meetings taking place January 7-8, 2019.

Related Content